Indoximod
DRACPC ID DRACPC0091
Active Ingredients Indoximod
Description A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy.
Synonyms 1-Methyl-D-tryptophan; 1-MT; D-(+)-1-Methyltryptophan; D-1MT; Indoximod
Type Small Molecule
Disease Glioma, Melanoma, Ependymoma, Gliosarcoma, Lung Cancer
Classification
Enzyme IDO inhibitor Amino acid and derivative Immunosuppressant
Structure Information
Molecular Formula C12H14N2O2
Molecular Weight 218.3
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid
InChI InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m1/s1
InChI_Key ZADWXFSZEAPBJS-SNVBAGLBSA-N
SMILES O=C(O)[C@H](N)CC1=CN(C)C2=C1C=CC=C2
External Codes
PubChem CID 405012
DrugBank Accession Number DB12827
NCI Thesaurus Code C71535
UNII TX5CYN1KMZ GSRS
CAS 110117-83-4
Drug approval
Drug indication
Indoximod has been used in trials studying the treatment of Glioma, Melanoma, Ependymoma, Gliosarcoma, and Lung Cancer, among others.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT01560923 | A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer | Metastatic Prostate Cancer | Phase 2 | Treatment |
| NCT02835729 | A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | Phase 1 | Treatment |
| NCT03301636 | A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Adult Patients With Unresectable Stage III or Stage IV Malignant Melanoma | Melanoma | Phase 2/3 | Treatment |
| NCT05106296 | Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer | Ependymoma; Medulloblastoma; Glioblastoma; Primary Brain Tumor | Phase 1 | Treatment |
| NCT01042535 | A Phase 1/2 Study of Ad.p53 DC Vaccine in Combination With 1-methyl-D-tryptophan in Metastatic Solid Tumors and Invasive Breast Cancer | Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific | Phase 1/2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
